Navigation Links
VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
Date:7/28/2015

VetStem Biopharma will be offering weekly private guided tours of our new facility, followed by a live stem cell credentialing course to local area veterinarians.

The tour and course will be given every Wednesday at 6pm to local interested veterinarians (3 RACE approved CE units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. Participants will be able to tour the new GMP facility, where stem cell products will be produced under 3 FDA INAD’s. Participants will learn about Regenerative Medicine, with in-depth information on stem cell therapy in particular. After completing this course, these local practitioners will be equipped to offer this exciting treatment modality to their patients that suffer from osteoarthritis and tendon, ligament and muscle issues.

VetStem continues to strive to bring the best Regenerative Medicine therapies to veterinarians to help provide better quality of life for animals. VetStem is currently providing stem cell services for two studies, one at a university and one at a major non-profit animal medical center. In addition to this, VetStem is working with individual veterinarians to learn more about how stem cell therapy works in animals with immune mediated diseases.

About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Contact
VetStem Biopharma , Inc
Kristi Hauta
Marketing Operation Manager
858-748-2004 ext 208
khauta@vetstem.com

Read the full story at http://www.prweb.com/releases/2015/07/prweb12864800.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
2. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
3. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
4. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
5. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
6. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
7. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
8. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
9. Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics
10. Edison Initiates Coverage on PDL BioPharma
11. MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... ... August 11, 2020 , ... ... engineering firm, is making available for free its new white paper – ... transport simulation testing into today’s biologics licensing application (BLA). In response, Modality ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – ... , Known as MediVet Biologics since its formation in 2016, ... The new Ardent Animal Health will build on its base of innovative therapies for ...
(Date:7/31/2020)... ... 2020 , ... Anomet Products has introduced new custom composite ... with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad Wire ... and cost criteria; especially where solid wire is limited. Typical configurations for implantable ...
(Date:7/31/2020)... (PRWEB) , ... July 30, ... ... of cloud-based software for the life sciences industry, today announced the release ... platform designed specifically for Medical Science Liaisons (MSLs) and other field medical ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company ... U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
Breaking Biology News(10 mins):